<DOC>
	<DOC>NCT02127866</DOC>
	<brief_summary>The purpose of this study is to determine the optimal dose of CHF 5259 (glycopyrrolate bromide) on top of Foster which provides the optimal additive bronchodilator effect to asthmatic patients whose symptoms are uncontrolled with medium dose of inhaled corticosteroids plus long acting beta2 agonists.</brief_summary>
	<brief_title>Triple in Asthma Dose Finding</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Beclomethasone</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Glycopyrrolate</mesh_term>
	<criteria>Male or female patients aged &gt;=18 years Uncontrolled asthma on medium doses of ICS+LABA with ACQ &gt;=1.5 Prebronchodilator FEV1 â‰¥40% and &lt;80% of their predicted normal value Pregnant or lactating women Diagnosis of COPD Patients treated for asthma exacerbations in the 4 weeks prior to study entry Patients who are in therapy for gastroesophageal reflux disease Patients who have a clinically significant cardiovascular condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Asthma, anticholinergics</keyword>
</DOC>